Depiction of microglial activation in aging and dementia: Positron emission tomography with [ 11 C]DPA713 versus [ 11 C](R)PK11195

Journal of Cerebral Blood Flow and Metabolism

Volumn 37, Issue 3, 2017, Pages 877-889

  Yokokura, Masamichi ^a   Terada, Tatsuhiro ^a   Bunai, Tomoyasu ^a   Nakaizumi, Kyoko ^a   Takebayashi, Kiyokazu ^a   Iwata, Yasuhide ^a   Yoshikawa, Etsuji ^b   Futatsubashi, Masami ^b   Suzuki, Katsuaki ^a   Mori, Norio ^a   Ouchi, Yasuomi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CENTRAL RESEARCH LABORATORY   (Japan)

Author keywords

Aging; brain imaging; dementia; microglia; positron emission tomography

Indexed keywords

DPA 713 C 11; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ACETAMIDE DERIVATIVE; CARBON; ISOQUINOLINE DERIVATIVE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; N,N-DIETHYL-2-(2-(4-METHOXYPHENYL)-5,7-DIMETHYL-PYRAZOLO(1,5-A)PYRIMIDIN-3-YL)-ACETAMIDE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; AGING; ALZHEIMER DISEASE; AMYGDALA; ANTERIOR CINGULATE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CAUDATE NUCLEUS; CELL ACTIVATION; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; LATERAL PARIETAL CORTEX; LATERAL TEMPORAL CORTEX; MALE; MEDIAL FRONTAL CORTEX; MICROGLIA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OCCIPITAL CORTEX; PARAHIPPOCAMPAL CORTEX; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; PRIORITY JOURNAL; PUTAMEN; SUPERIOR FRONTAL CORTEX; THALAMUS; VERY ELDERLY; YOUNG ADULT; BRAIN; CYTOLOGY; DEMENTIA; METABOLISM; PATHOLOGY; PROCEDURES;

ACETAMIDES; AGED; AGING; ALZHEIMER DISEASE; BRAIN; CARBON RADIOISOTOPES; DEMENTIA; HUMANS; ISOQUINOLINES; MICROGLIA; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; PYRIMIDINES; YOUNG ADULT;

EID: 85012150904     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1177/0271678X16646788     Document Type: Article

References (42)

1. Gulyas B, Makkai B, Kasa P, et al. A comparative autoradiography study in post mortem whole hemisphere human brain slices taken from Alzheimer patients and age-matched controls using two radiolabelled DAA1106 analogues with high affinity to the peripheral benzodiazepine receptor (PBR) system. Neurochem Int 2009; 54: 28-36.
2. Sheng JG, Mrak RE and Griffin WS. Enlarged and phagocytic, but not primed, interleukin-1 alpha-immunoreactive microglia increase with age in normal human brain. Acta Neuropathol 1998; 95: 229-234.
3. Venneti S, Wiley CA and Kofler J. Imaging microglial activation during neuroinflammation and Alzheimers disease. J Neuroimmune Pharmacol: Off J Soc NeuroImmune Pharmacol 2009; 4: 227-243.
4. Frank MG, Barrientos RM, Watkins LR, et al. Aging sensitizes rapidly isolated hippocampal microglia to LPS ex vivo. J Neuroimmunol 2010; 226: 181-184.
5. Sloane JA, Hollander W, Moss MB, et al. Increased microglial activation and protein nitration in white matter of the aging monkey. Neurobiol Aging 1999; 20: 395-405.
6. Lekander M, von Essen J, Schultzberg M, et al. Cytokines and memory across the mature life span of women. Scand J Psychol 2011; 52: 229-235.
7. McGeer EG and McGeer PL. The importance of inflammatory mechanisms in Alzheimer disease. Exp Gerontol 1998; 33: 371-378.
8. Barrientos RM, Kitt MM, Watkins LR, et al. Neuroinflammation in the normal aging hippocampus. Neuroscience 2015; 309: 84-99.
9. Latta CH, Brothers HM and Wilcock DM. Neuroinflammation in Alzheimers disease: A source of heterogeneity and target for personalized therapy. Neuroscience 2015; 302: 103-111.
10. Suzuki K, Sugihara G, Ouchi Y, et al. Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatr 2013; 70: 49-58.
11. Venneti S, Wang G, Nguyen J, et al. The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disorders. J Neuropathol Exp Neurol 2008; 67: 1001-1010.
12. Yokokura M, Mori N, Yagi S, et al. In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimers disease. Eur J Nucl Med Mol Imaging 2011; 38: 343-351.
13. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinsons disease. Ann Neurol 2005; 57: 168-175.
14. Kumar A, Muzik O, Shandal V, et al. Evaluation of agerelated changes in translocator protein (TSPO) in human brain using (11)C-[R]-PK11195 PET. J Neuroinflam 2012; 9: 232-241.
15. Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet 2001; 358: 461-467.
16. Wiley CA, Lopresti BJ, Venneti S, et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 2009; 66: 60-67.
17. Schuitemaker A, Kropholler MA, Boellaard R, et al. Microglial activation in Alzheimers disease: An (R)-[(1)(1)C]PK11195 positron emission tomography study. Neurobiol Aging 2013; 34: 128-136.
18. Yasuno F, Ota M, Kosaka J, et al. Increased binding of peripheral benzodiazepine receptor in Alzheimers disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry 2008; 64: 835-841.
19. Kreisl WC, Lyoo CH, McGwier M, et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimers disease. Brain 2013; 136: 2228-2238.
20. Gulyas B, Vas A, Toth M, et al. Age and disease related changes in the translocator protein (TSPO) system in the human brain: positron emission tomography measurements with [11C]vinpocetine. Neuroimage 2011; 56: 1111-1121.
21. Varrone A, Mattsson P, Forsberg A, et al. In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimers disease patients. Eur J Nucl Med Mol Imaging 2013; 40: 921-931.
22. Golla SS, Boellaard R, Oikonen V, et al. Quantification of [18F]DPA-714 binding in the human brain: initial studies in healthy controls and Alzheimers disease patients. J Cereb Blood Flow Metab 2015; 35: 766-772.
23. Boutin H, Chauveau F, Thominiaux C, et al. 11C-DPA-713: A novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of neuroinflammation. J Nucl Med 2007; 48: 573-581.
24. Endres CJ, Pomper MG, James M, et al. Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med 2009; 50: 1276-1282.
25. Owen DR, Yeo AJ, Gunn RN, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 2012; 32: 1-5.
26. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 1984; 34: 939-944.
27. Ouchi Y, Nobezawa S, Okada H, et al. Altered glucose metabolism in the hippocampal head in memory impairment. Neurology 1998; 51: 136-142.
28. Watanabe M, Shimizu K, Omura T, et al. A new highresolution PET scanner dedicated to brain research. IEEE Trans Nucl Sci 2002; 49: 634-639.
29. Lammertsma AA and Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4: 153-158.
30. Ashburner J, Haslam J, Taylor C, et al. A cluster analysis approach for the characterization of dynamic PET data. Quantification of brain function using PET. San Diego: Academic Press, 1996, pp.301-306.
31. Barrientos RM, Hein AM, Frank MG, et al. Intracisternal interleukin-1 receptor antagonist prevents postoperative cognitive decline and neuroinflammatory response in aged rats. J Neurosci 2012; 32: 14641-14648.
32. Abraham J and Johnson RW. Consuming a diet supplemented with resveratrol reduced infection-related neuroinflammation and deficits in working memory in aged mice. Rejuvenation Res 2009; 12: 445-453.
33. Barrientos RM, Frank MG, Crysdale NY, et al. Little exercise, big effects: reversing aging and infection-induced memory deficits, and underlying processes. J Neurosci 2011; 31: 11578-11586.
34. Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimers disease. Ann Neurol 1997; 42: 85-94.
35. Dickens AM, Vainio S, Marjamaki P, et al. Detection of microglial activation in an acute model of neuroinflammation using PET and radiotracers 11C-(R)-PK11195 and 18F-GE-180. J Nucl Med 2014; 55: 466-472.
36. Sudduth TL, Schmitt FA, Nelson PT, et al. Neuroinflammatory phenotype in early Alzheimers disease. Neurobiol Aging 2013; 34: 1051-1059.
37. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 2004; 24: 6144-6151.
38. McGeer PL and McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007; 28: 639-647.
39. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimers disease. J Neurosci 2000; 20: 5709-5714.
40. Breitner JC, Baker LD, Montine TJ, et al. Extended results of the Alzheimers disease anti-inflammatory prevention trial. Alzheimers Dement 2011; 7: 402-411.
41. Yasuno F, Kosaka J, Ota M, et al. Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with [(1)(1)C]DAA1106. Psychiatr Res 2012; 203: 67-74.
42. Owen DR, Gunn RN, Rabiner EA, et al. Mixed-Affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med 2011; 52: 24-32.